Showing 8131-8140 of 10543 results for "".
- Moisturizer Effective in Acne Patients Using Topical Therapies: Analysishttps://practicaldermatology.com/news/moisturizer-boosts-skin-barrier-in-acne-patients-using-topical-therapies/2484743/New research showed a novel gel-matrix moisturizer improving skin barrier function and overall skin quality in adults with acne undergoing topical treatment. Researchers from Kenvue and Dermatology Consulting Services evaluated
- ODAC 2026 Adds Hands-On, High-Impact Workshopshttps://practicaldermatology.com/news/odac-2026-adds-hands-on-high-impact-workshops/2484689/The ODAC Dermatology Conference will return to Orlando, Florida, in 2026 with a refreshed slate of interactive, expert-led sessions that emphasize skill-building across medical, surgical, and aesthetic dermatology, organizers said in a press release. Scheduled for J
- Analysis: Machine Learning Model Outperforms Existing Melanoma Prognostic Toolshttps://practicaldermatology.com/news/analysis-machine-learning-model-outperforms-existing-melanoma-prognostic-tools/2484593/A new machine learning-based model may offer clinicians a more accurate method for predicting prognosis in patients with cutaneous melanoma, according to a study published in Experimental Dermatology.
- Platform Prints First Collagen-Based Bioink for Personalized Tissue Creationhttps://practicaldermatology.com/news/platform-prints-first-collagen-based-bioink-for-personalized-tissue-creation/2484559/Conexeu Sciences Inc. has announced the first 3D-printed tissue scaffolds created entirely from its proprietary extracellular matrix (ECM), according to a release from the manufacturer. Conexeu said their CXU™ platform, a bovin
- Tralokinumab Maintains Efficacy in Hand AD Through 32 Weekshttps://practicaldermatology.com/news/tralokinumab-maintains-efficacy-in-hand-ad-through-32-weeks/2484484/LEO Pharma has announced positive 32-week topline results from its ADHAND trial, a phase 3b study evaluating tralokinumab in adults with moderate-to-severe atopic dermatitis (AD) with hand involvement. According to a press rele
- Novartis Launches Head-to-Head Trial of Remibrutinib vs Dupilumabhttps://practicaldermatology.com/news/novartis-launches-head-to-head-trial-of-remibrutinib-vs-dupilumab/2484430/Novartis, manufacturers of remibrutinib (Rhapsido), announced the launch of a US-based phase 3b clinical trial for the evaluation of early efficacy and safety of oral remibrutinib compared to injectable dupilumab in adults with chronic spontaneous urticaria (CSU) in
- NICE Recommends First Topical JAK Inhibitor for CHE in England and Waleshttps://practicaldermatology.com/news/nice-recommends-first-topical-jak-inhibitor-for-che-in-england-and-wales/2484333/The National Institute for Health and Care Excellence (NICE) has recommended the reimbursement of Anzupgo® (delgocitinib) cream for adult patients with moderate to severe chronic hand eczema (CHE) who have not responded to,
- Incyte Opens Applications for HS-Focused Ingenuity Awardshttps://practicaldermatology.com/news/incyte-opens-applications-for-hs-focused-ingenuity-awards/2484308/Incyte has announced the launch of the Incyte Ingenuity Awards (IIA) in Hidradenitis Suppurativa (HS), a new initiative developed in collaboration with patients, advocates, and clinicians to address challenges faced by HS patients, according to a press release from
- Lebrikizumab Maintains Efficacy With Reduced Dosing Intervalhttps://practicaldermatology.com/news/lebrikizumab-maintains-efficacy-with-reduced-dosing-interval/2484255/Long-term data from a 32-week extension of the ADjoin trial suggest that lebrikizumab, an IL-13 inhibitor approved for once-monthly dosing, may maintain clinical efficacy in patients with moderate-to-severe atopic dermatitis (AD) even when administered once every 8
- Neutrogena Recalls Makeup Wipes Due to Bacterial Contaminationhttps://practicaldermatology.com/news/neutrogena-recalls-makeup-wipes-due-to-bacterial-contamination/2484214/The Food and Drug Administration (FDA) issued a Class II risk level for a line of Neutrogena's makeup-removing facial wipes due to potential bacterial infection, according to a statement from the agency. In a brief message, the FDA reported that an internal investigation by the manufacture